TL-895 是一种有效的，具有口服活性的，ATP 竞争性的，高度选择性不可逆 BTK 抑制剂，其 IC50 和 Ki 值分别为 1.5 nM 和 11.9 nM。TL-895 可用于 JAKi 复发/难治性骨髓纤维化、急性髓系白血病、COVID-19 和癌症研究。
货号:ajcx35270
CAS:1415823-49-2
分子式:C25H26FN5O2
分子量：447.5
溶解度:DMSO : 250 mg/mL (558.66 mM; Need ultrasonic)
纯度：98%
存储：Store at -20°C
库存：现货

Background:

TL-895 is a potent, orally active, ATP-competitive, and highly selective irreversible BTK inhibitor with an IC50 and a Ki of 1.5 nM and 11.9 nM, respectively[1]. TL-895 is used be for JAKi-relapsed/refractory myelofibrosis, acute myeloid leukemia, COVID-19 and cancer research[2][3][4].

[1]. Richard D Caldwell, et al. Discovery of Evobrutinib: An Oral, Potent, and Highly Selective, Covalent Bruton’s Tyrosine Kinase (BTK) Inhibitor for the Treatment of Immunological Diseases. J Med Chem. 2019 Sep 12;62(17):7643-7655. [2]. Valeria Di Battista, et al. Genetics and Pathogenetic Role of Inflammasomes in Philadelphia Negative Chronic Myeloproliferative Neoplasms: A Narrative Review. Int J Mol Sci
[3]. A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer
[4]. Study of TL-895 in Subjects With Myelofibrosis